JP2021530565A5 - - Google Patents

Download PDF

Info

Publication number
JP2021530565A5
JP2021530565A5 JP2021525358A JP2021525358A JP2021530565A5 JP 2021530565 A5 JP2021530565 A5 JP 2021530565A5 JP 2021525358 A JP2021525358 A JP 2021525358A JP 2021525358 A JP2021525358 A JP 2021525358A JP 2021530565 A5 JP2021530565 A5 JP 2021530565A5
Authority
JP
Japan
Prior art keywords
crystalline
compound iii
type
angles
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021525358A
Other languages
English (en)
Japanese (ja)
Other versions
JP7358466B2 (ja
JP2021530565A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/096842 external-priority patent/WO2020015745A1/zh
Publication of JP2021530565A publication Critical patent/JP2021530565A/ja
Publication of JP2021530565A5 publication Critical patent/JP2021530565A5/ja
Application granted granted Critical
Publication of JP7358466B2 publication Critical patent/JP7358466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021525358A 2018-07-20 2019-07-19 Lsd1阻害剤の塩及びその結晶型 Active JP7358466B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810804068.3 2018-07-20
CN201810804068 2018-07-20
PCT/CN2019/096842 WO2020015745A1 (zh) 2018-07-20 2019-07-19 一种lsd1抑制剂的盐及其晶型

Publications (3)

Publication Number Publication Date
JP2021530565A JP2021530565A (ja) 2021-11-11
JP2021530565A5 true JP2021530565A5 (enExample) 2021-12-23
JP7358466B2 JP7358466B2 (ja) 2023-10-10

Family

ID=69163657

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021525358A Active JP7358466B2 (ja) 2018-07-20 2019-07-19 Lsd1阻害剤の塩及びその結晶型

Country Status (8)

Country Link
US (1) US12024494B2 (enExample)
EP (1) EP3825309B1 (enExample)
JP (1) JP7358466B2 (enExample)
KR (1) KR102778948B1 (enExample)
CN (1) CN112424175B (enExample)
AU (1) AU2019303777B2 (enExample)
CA (1) CA3106484C (enExample)
WO (1) WO2020015745A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021228146A1 (zh) * 2020-05-12 2021-11-18 石药集团中奇制药技术(石家庄)有限公司 一种lsd1抑制剂的用途
CA3231846A1 (en) 2021-04-08 2022-10-13 Tamara Maes Combinations of lsd1 inhibitors for treating myeloid cancers
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
AU2023385514A1 (en) 2022-11-24 2025-07-10 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
CN116069221A (zh) * 2022-12-27 2023-05-05 北京字跳网络技术有限公司 媒体内容的展示方法、装置、电子设备和存储介质
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705675B1 (fr) * 1993-05-27 1996-05-03 Smithkline Beecham Labo Pharma Nouveaux composés, leur procédé de préparation et leur utilisation en tant que médicaments.
WO2010084160A1 (en) * 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
ES2607081T3 (es) 2010-04-19 2017-03-29 Oryzon Genomics, S.A. Inhibidores de desmetilasa específica de lisina-1 y su uso
LT2598482T (lt) 2010-07-29 2018-07-10 Oryzon Genomics, S.A. Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas
CN103857393B (zh) 2011-03-25 2016-08-17 葛兰素史密斯克莱知识产权(第2号)有限公司 环丙基胺作为lsd1抑制剂
KR102710120B1 (ko) * 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
PE20190377A1 (es) * 2016-04-22 2019-03-08 Incyte Corp Formulaciones de un inhibidor de lsd 1
CA3022561A1 (en) 2016-05-09 2017-11-16 Sridharan Rajagopal Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
RU2763898C9 (ru) 2017-01-24 2022-03-18 Цспц Чжунци Фармасьютикал Текнолоджи (Шицзячжуан) Ко., Лтд. Ингибитор lsd1, а также способ его получения и его применение

Similar Documents

Publication Publication Date Title
JP2021530565A5 (enExample)
JP2023082086A5 (enExample)
JP2010516681A5 (enExample)
JP2019504103A5 (enExample)
JP2019514863A5 (enExample)
JP2022183220A5 (enExample)
JP2016121196A5 (enExample)
JP2020511467A5 (enExample)
JP2018193382A5 (enExample)
JP2023036708A5 (enExample)
JP2014524442A5 (enExample)
JP2014530818A5 (enExample)
JP2013538849A5 (enExample)
JP2019505533A5 (enExample)
JP2016510768A5 (enExample)
JP2021514967A5 (enExample)
RU2019100065A (ru) Кристаллы анилинпиримидинового соединения, действующего в качестве ингибитора EGFR
CN111819177A (zh) 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法
JP2014524476A5 (enExample)
JP2019516749A5 (enExample)
CN115315423A (zh) 取代芳基类化合物
JP2016537326A5 (enExample)
CN114430736A (zh) 含有n杂五元环的衣壳蛋白装配抑制剂的晶型及其应用
JP2016510767A5 (enExample)
RU2012136148A (ru) Новая кристаллическая форма производного циклопропилбензамида